Sam Jactel
Direttore/Membro del Consiglio presso Hypercell Technologies, Inc.
Profilo
Sam Jactel currently works as a Director at Hypercell Technologies, Inc.
Posizioni attive di Sam Jactel
Società | Posizione | Inizio |
---|---|---|
Hypercell Technologies, Inc.
Hypercell Technologies, Inc. Packaged SoftwareTechnology Services Hypercell Technologies, Inc. has developed a proprietary point-of-care diagnostic technology platform that allows for the early identification and management of biological contaminants in the food chain, from production to transformation. The private company is based in Brookhaven, GA and was founded by Bruno Jactel, who has been the CEO since incorporation. Despite advances in vaccines and testing tools, production animal diseases still cost $10 billion in lost productivity and threaten the human population when animal diseases jump to the human species. Food-borne diseases impact 48 million Americans every year and cost the economy more than $55 billion/year. Hypercell's solution is as accurate as the gold standard PCR, 10x faster, and without expensive lab equipment. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Hypercell Technologies, Inc.
Hypercell Technologies, Inc. Packaged SoftwareTechnology Services Hypercell Technologies, Inc. has developed a proprietary point-of-care diagnostic technology platform that allows for the early identification and management of biological contaminants in the food chain, from production to transformation. The private company is based in Brookhaven, GA and was founded by Bruno Jactel, who has been the CEO since incorporation. Despite advances in vaccines and testing tools, production animal diseases still cost $10 billion in lost productivity and threaten the human population when animal diseases jump to the human species. Food-borne diseases impact 48 million Americans every year and cost the economy more than $55 billion/year. Hypercell's solution is as accurate as the gold standard PCR, 10x faster, and without expensive lab equipment. | Technology Services |
- Borsa valori
- Insiders
- Sam Jactel